.jpeg)
2026-08-31 03:37:12
The combination is approved for first-line treatment of locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitutions, with PFS and OS advantages over osimertinib in MARIPOSA.
2026-08-31 03:30:32
Midostaurin is an oral multi-kinase inhibitor approved for FLT3 mutation–positive newly diagnosed AML and for ASM, SM-AHN and MCL — with distinctly different dosing for each indication.
2026-08-31 03:26:31
Lapatinib is an oral reversible dual EGFR/HER2 tyrosine kinase inhibitor used in previously treated HER2-positive advanced or metastatic breast cancer to delay disease progression.
2026-08-31 03:03:03
Filgotinib (Jyseleca) is a selective JAK1 inhibitor approved overseas for moderate-to-severe rheumatoid arthritis and ulcerative colitis. This article outlines its indications, mechanism, infection risks, long-term safety, and monitoring.
2026-08-31 02:30:28
On August 27, 2026, the FDA approved once-daily oral brepocitinib 30 mg for adults with dermatomyositis — the first targeted and first oral therapy ever approved for the disease.
2026-08-28 07:03:42
Elagolix (brand name Orilissa) is FDA-approved for moderate to severe pain caused by endometriosis, including painful periods. This article explains its mechanism, who should use it, and safety limits.
2026-08-28 06:59:42
Bosentan is an endothelin receptor antagonist used for pulmonary arterial hypertension (PAH), not common high blood pressure. This article explains the difference and precautions for concurrent use.
2026-08-28 06:56:21
Letermovir is used to prevent cytomegalovirus (CMV) infection in transplant patients. This article details the administration methods for tablets and granules, dosage requirements, and drug interactions, emphasizing the importance of following medical advice.
2026-08-28 06:51:52
In August 2026, the U.S. FDA granted accelerated approval to daraxonrasib (Rasonque), an oral RAS(ON) inhibitor developed by Revolution Medicines. The drug significantly improves survival in metastatic pancreatic cancer, reshaping the treatment landscape.
2026-08-27 07:16:18
Brensocatib (Brinsupri) is the first FDA-approved disease-modifying therapy for non-cystic fibrosis bronchiectasis. Based on the ASPEN Phase 3 trial, it significantly reduces annual exacerbation rates and slows lung function decline. This article details patient selection, efficacy data, and safety management.
2026-08-27 07:05:19
Mirdametinib is a MEK1/2 inhibitor approved by the FDA for symptomatic, inoperable plexiform neurofibromas in patients with NF1 aged 2 years and older. This article explains its mechanism, ReNeu trial data, and targeted therapy value.
2026-08-27 05:38:45
In August 2026, the FDA approved zanidatamab (Ziihera) in combination with tislelizumab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma, achieving a median OS of 26.4 months. This article details the clinical data, indications, safety warnings, and dosing guidelines.
